Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

Existe información en español para pacientes y cuidadores, para acceder, haga clic sobre “Select” al lado de “I am a U.S. Patient / Caregiver”.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

TAZICEF - VIAL Principal Display Panel (ceftazidime for injection, USP - VIAL)

PRINCIPAL DISPLAY PANEL - 2 g Vial Label

NDC 0409-5084-13

equivalent to
2 g/vial ceftazidime

TAZICEF®
Ceftazidime For
Injection, USP

For intravenous use

Single-dose vial

Rx only

Hospira

PRINCIPAL DISPLAY PANEL - 2 g Vial Label

PRINCIPAL DISPLAY PANEL - 2 g Vial Tray Label

NDC 0409-5084-11

equivalent to
2 g/vial ceftazidime

TAZICEF®
Ceftazidime For
Injection, USP

10 Single-dose vials

Rx only

Hospira

Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room
Temperature].

IMPORTANT: This vial is under reduced pressure. Addition of
diluent generates a positive pressure. Before reconstituting,
see Instructions for Reconstitution.

Usual Adult Dosage: 1 gram every 8 to 12 hours. In severe,
refractory or life-threatening infections, 2 grams every 8 hours. See
accompanying prescribing information for reconstitution, dosage
and administration instructions.
Properly reconstituted solutions of Tazicef are stable for 24 hours at
room temperature or 7 days if refrigerated. Slight yellowing does
not affect potency.
Each vial contains ceftazidime pentahydrate equivalent to
2 grams of ceftazidime and 236 mg of sodium carbonate.
(Sodium content is approximately 54 mg or 2.3 mEq per gram of
ceftazidime activity.)

Manufactured by Sandoz GmbH for Hospira, Inc., Lake Forest,
IL 60045, USA
MADE IN CHINA

46287819.

PRINCIPAL DISPLAY PANEL - 2 g Vial Tray Label

PRINCIPAL DISPLAY PANEL - 1 g Vial Label

NDC 0409-5082-11

equivalent to
1 g/vial ceftazidime

TAZICEF®
Ceftazidime For
Injection, USP

For intravenous or intramuscular use.

Single-dose vial

Rx only

Hospira

PRINCIPAL DISPLAY PANEL - 1 g Vial Label

PRINCIPAL DISPLAY PANEL - 1 g Vial Carton Label

NDC 0409-5082-16

equivalent to
1 g/vial ceftazidime

TAZICEF®
Ceftazidime For
Injection, USP

25 Single-dose vials

Rx only

Hospira

Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature].

IMPORTANT: This vial is under reduced pressure. Addition of diluent generates
a positive pressure. Before reconstituting, see Instructions for Reconstitution.
Usual Adult Dosage: 1 gram every 8 to 12 hours. See accompanying prescribing
information for reconstitution, dosage and administration instructions. Properly
reconstituted solutions of Tazicef are stable for 24 hours at room temperature
or 7 days if refrigerated. Slight yellowing does not affect potency.
Each vial contains ceftazidime pentahydrate equivalent to 1 gram of ceftazidime
and 118 mg of sodium carbonate. (Sodium content is approximately 54 mg or
2.3 mEq per gram of ceftazidime activity.)

Manufactured by Sandoz
GmbH for Hospira, Inc.,
Lake Forest, IL 60045, USA

MADE IN CHINA

46287963.

PRINCIPAL DISPLAY PANEL - 1 g Vial Carton Label
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event